ICIs recover the immune system’s ability to attack cancer through binding to immune checkpoint molecules, such as programmed death receptor-1 (PD-1), programmed death receptor ligand-1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4) [8]. This evidence concerns the gene CD274 and cancer.